Trials / Unknown
UnknownNCT04014101
SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma
A Single Arm Pilot Study of Programmed Cell Death Protein 1 Antibody (PD-1# SHR-1210 Combined With Apatinib Mesylate in Patients With Advanced-Stage Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label#single center #non-randomized #Single Arm Exploratory Study . This clinical study is an investigator-initiated clinical trial(IIT) .The objective of this study is to evaluate the efficacy and safety of therapy with anti-PD-1 antibody SHR-1210 and apatinib in patients with advanced stage hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1210 | SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody |
| DRUG | apatinib | Apatinib is a selective VEGFR2 inhibitor. |
Timeline
- Start date
- 2019-06-01
- Primary completion
- 2019-10-01
- Completion
- 2020-10-01
- First posted
- 2019-07-10
- Last updated
- 2019-07-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04014101. Inclusion in this directory is not an endorsement.